Company news

Eledon Pharmaceuticals, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual Meeting

October 26, 2026

Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting

October 5, 2026

Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

September 22, 2026

Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society

September 9, 2026

Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026

September 3, 2026

Eledon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 13, 2026

Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared with Tacrolimus

June 22, 2026

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

June 7, 2026

Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions

June 4, 2026

Eledon Pharmaceuticals to Present New Long-Term Data from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at American Transplant Congress

May 20, 2026

Eledon Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 13, 2026

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results

March 19, 2026

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at UChicago Medicine

March 15, 2026

Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation

March 9, 2026

Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference

March 4, 2026

Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 5, 2026

Eledon Pharmaceuticals Presents Long-Term Phase 1b Data for Tegoprubart in Kidney Transplant Patients at the American Society of Transplant Surgeons Winter Symposium

January 23, 2026

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2026 Outlook

January 8, 2026

Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference

December 1, 2025

Eledon Reports Preliminary Data from First Six Patients with Type 1 Diabetes Treated with Tegoprubart as the Core Immunosuppressant Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

November 18, 2025

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2025 Financial Results

November 14, 2025

Eledon Pharmaceuticals Announces Pricing of $50 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants

November 12, 2025

Eledon Pharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

November 11, 2025

Eledon Presents Phase 2 BESTOW Trial Results for Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology’s Kidney Week 2025 Annual Meeting

November 6, 2025

Eledon Pharmaceuticals to Present at Guggenheim Second Annual Healthcare Innovation Conference

November 5, 2025

Eledon Pharmaceuticals to Present Results from Phase 2 BESTOW Trial of Tegoprubart for the Prevention of Rejection in Kidney Transplantation at the American Society of Nephrology Kidney Week 2025 Annual Meeting

October 17, 2025

Eledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation Association

September 24, 2025

Eledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025

August 29, 2025

Eledon Pharmaceuticals Reports Second Quarter 2025 Operating and Financial Results

August 14, 2025

Eledon Presents Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

August 6, 2025

Eledon Pharmaceuticals to Host a Conference Call to Discuss Updated Data from the Ongoing Phase 1b Trial of Tegoprubart in Kidney Transplantation Being Presented at the World Transplant Congress 2025

July 30, 2025

Updated Data from Eledon Pharmaceuticals’ Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation to be Presented at the World Transplant Congress 2025

July 17, 2025

Eledon Pharmaceuticals to Host R&D Day on July 9, 2025 in New York City

June 25, 2025

Eledon Pharmaceuticals Reports First Quarter 2025 Operating and Financial Results

May 14, 2025

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results

March 20, 2025

Eledon Pharmaceuticals to Participate in Leerink Partners Global Healthcare Conference

March 4, 2025

Eledon Pharmaceuticals Announces Use of Tegoprubart as Key Component of Immunosuppression Regimen in its Second Transplant of a Genetically Modified Pig Kidney into a Human

February 6, 2025

Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

November 11, 2024

Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

October 28, 2024

Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

October 28, 2024

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

September 3, 2024

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

August 13, 2024

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

July 28, 2024

Eledon Pharmaceuticals Reports First Quarter 2024 Operating and Financial Results

May 8, 2024

Eledon Pharmaceuticals Announces Oversubscribed $50 Million Private Placement

May 6, 2024

Eledon Announces Clinical Progress with Tegoprubart in the Prevention of Transplant Rejection

May 6, 2024

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

March 27, 2024

Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

March 24, 2024

Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

March 20, 2024

Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 12, 2024

Older news releases →

Calls

The 5 newest of 10 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.